Immunity to RSV in early-life

Frontiers in Immunology

Volumn 5, Issue SEP, 2014, Pages

  Lambert, Laura ^a   Sagfors, Agnes M ^a   Openshaw, Peter J M ^a   Culley, Fiona J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Bronchiolitis; Mucosal immunology; Neonatal; Respiratory; RSV; Viral

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8;

ADULT; AGRICULTURAL WORKER; BIOPSY; CANCER STAGING; CASE REPORT; CELL DIFFERENTIATION; CELL GROWTH; CHEEK MUCOSA; COMPUTER ASSISTED TOMOGRAPHY; DEATH; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MOUTH EXAMINATION; MOUTH LESION; MOUTH SQUAMOUS CELL CARCINOMA; MOUTH ULCER; NECK DISSECTION; RADIATION DOSE; REVIEW; SQUAMOUS CELL;

EID: 84919386656     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00466     Document Type: Review

References (203)

1. Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med (1956) 92:544-9. doi: 10.3181/00379727-92-22538
2. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent. I. Isolation, properties and characterization. Am J Hyg (1957) 66:281-90.
3. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (2010) 375:1545-55. doi:10.1016/S0140-6736(10)60206-1
4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med (2009) 360:588-98. doi:10.1056/NEJMoa0804877
5. Mufson MA, örvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol (1985) 66:2111-24. doi:10.1099/0022-1317-66-10-2111
6. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A (2013) 110:11133-8. doi:10.1073/pnas.1309070110
7. Kiss G, Holl JM, Williams GM, Alonas E, Vanover D, Lifland AW, et al. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. J Virol (2014) 88:7602-17. doi:10.1128/JVI.00256-14
8. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Arch Pediatr Adolesc Med (1986) 140:543-6. doi:10.1001/archpedi.1986.02140200053026
9. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev (2010) 23:74-98. doi:10.1128/CMR.00032-09
10. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One (2014) 9:e89186. doi:10.1371/journal.pone.0089186
11. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289:179-86. doi:10.1001/jama.289.2.179
12. van Asten L, Van Den Wijngaard C, Van Pelt W, Van DE, Kassteele J, Meijer A, et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis (2012) 206:628-39. doi:10.1093/infdis/jis415
13. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics (1998) 102:1774-93.
14. Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and Management of Bronchiolitis. Pediatrics (2006) 118:1774-93. doi:10.1542/peds.2006-2223
15. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis (2011) 204:996-1002. doi:10.1093/infdis/jir494
16. Moyes J, Cohen C, Pretorius M, Groome M, Von Gottberg A, Wolter N, et al. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J Infect Dis (2013) 208:S217-26. doi:10.1093/infdis/jit479
17. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr (2000) 137:78-84. doi:10.1067/mpd.2000.105350
18. García CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics (2010) 126:e1453-60. doi:10.1542/peds.2010-0507
19. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics (2013) 132:e341-8. doi:10.1542/peds.2013-0303
20. Mansbach JM, Piedra PA, Stevenson MD, Sullivan AF, Forgey TF, Clark S, et al. Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation. Pediatrics (2012) 130:e492-500. doi:10.1542/peds.2012-0444
21. Ferolla FM, Hijano DR, Acosta PL, Rodriguez A, Duenas K, Sancilio A, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med (2013) 187:983-90. doi:10.1164/rccm.201301-0016OC
22. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen EM, Kimpen JL, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics (2011) 127:e1513-20. doi:10.1542/peds.2010-3054
23. Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, Doornbos G, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis (2007) 196:826-34. doi:10.1086/520886
24. Thomsen SF, Stensballe LG, Skytthe A, Kyvik KO, Backer V, Bisgaard H. Increased concordance of severe respiratory syncytial virus infection in identical twins. Pediatrics (2008) 121:493-6. doi:10.1542/peds.2007-1889
25. Forton JT, Rowlands K, Rockett K, Hanchard N, Herbert M, Kwiatkowski DP, et al. Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster. Thorax (2009) 64:345-52. doi:10.1136/thx.2008.102111
26. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax (2000) 55:1023-7. doi:10.1136/thorax.55.12.1023
27. Hoebee B, Rietveld E, Bont L, Oosten MV, Hodemaekers HM, Nagelkerke NJD, et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor a polymorphisms. J Infect Dis (2003) 187:2-11. doi:10.1086/345859
28. Miyairi I, DeVincenzo JP. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev (2008) 21:686-703. doi:10.1128/CMR.00017-08
29. Fjaerli H-O, Bukholm G, Skjaeret C, Holden M, Nakstad B. Cord blood gene expression in infants hospitalized with respiratory syncytial virus bronchiolitis. J Infect Dis (2007) 196:394-404. doi:10.1086/519168
30. Ali S, Hirschfeld AF, Mayer ML, Fortuno ES, Corbett N, Kaplan M, et al. Functional genetic variation in NFKBIA and susceptibility to childhood asthma, bronchiolitis, and bronchopulmonary dysplasia. J Immunol (2013) 190:3949-58. doi:10.4049/jimmunol.1201015
31. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol (2006) 20:108-19. doi:10.1038/modpathol.3800725
32. Openshaw PJ. The mouse model of respiratory syncytial virus disease. Curr Top Microbiol Immunol (2013) 372:359-69. doi:10.1007/978-3-642-38919-1_18
33. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2008) 82:2040-55. doi:10.1128/JVI.01625-07
34. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis (2007) 195:1126-36. doi:10.1086/512615
35. Kolli D, Velayutham T, Casola A. Host-viral interactions: role of pattern recognition receptors (PRRs) in human pneumovirus infections. Pathogens (2013) 2:232-63. doi:10.3390/pathogens2020232
36. Marr N, Turvey SE, Grandvaux N. Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective. Trends Microbiol (2013) 21:568-74. doi:10.1016/j.tim.2013.08.006
37. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 1:398-401. doi:10.1038/80833
38. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol (2001) 75:10730-7. doi:10.1128/JVI.75.22.10730-10737.2001
39. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet (2000) 25:187-91. doi:10.1038/76048
40. Figueroa L, Xiong Y, Song C, Piao W, Vogel SN, Medvedev AE. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. J Immunol (2012) 188:4506-15. doi:10.4049/jimmunol.1200202
41. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, et al. Association between common toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis (2004) 189:2057-63. doi:10.1086/420830
42. Tulic MK, Hurrelbrink RJ, Prêle CM, Laing IA, Upham JW, LE Souef P, et al. TLR4 Polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol (2007) 179:132-40. doi:10.4049/jimmunol.179.1.132
43. Paulus SC, Hirschfeld AF, Victor RE, Brunstein J, Thomas E, Turvey SE. Common human toll-like receptor 4 polymorphisms-role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin Immunol (2007) 123:252-7. doi:10.1016/j.clim.2007.03.003
44. Löfgren J, Marttila R, Renko M, Rämet M, Hallman M. Toll-like receptor 4 Asp299Gly polymorphism in respiratory syncytial virus epidemics. Pediatr Pulmonol (2010) 45:687-92. doi:10.1002/ppul.21248
45. Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, Gruber A, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol (2006) 176:1937-42. doi:10.4049/jimmunol.176.3.1937
46. Lukacs NW, Smit JJ, Mukherjee S, Morris SB, Nunez G, Lindell DM. Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. J Immunol (2010) 185:2231-9. doi:10.4049/jimmunol.1000733
47. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol (2009) 183:7150-60. doi:10.4049/jimmunol.0901481
48. Pedraza-Sánchez S, Hise AG, Ramachandra L, Arechavaleta-Velasco F, King CL. Reduced frequency of a CD14+ CD16+ monocyte subset with high toll-like receptor 4 expression in cord blood compared to adult blood contributes to lipopolysaccharide hyporesponsiveness in newborns. Clin Vaccine Immunol (2013) 20:962-71. doi:10.1128/CVI.00609-12
49. Fonceca AM, Flanagan BF, Trinick R, Smyth RL, Mcnamara PS. Primary airway epithelial cultures from children are highly permissive to respiratory syncytial virus infection. Thorax (2012) 67:42-8. doi:10.1136/thoraxjnl-2011-200131
50. Villenave R, O'donoghue D, Thavagnanam S, Touzelet O, Skibinski G, Heaney LG, et al. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells. Virol J (2011) 8:43. doi:10.1186/1743-422X-8-43
51. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, et al. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A (2012) 109:5040-5. doi:10.1073/pnas.1110203109
52. Villenave R, Shields MD, Power UF. Respiratory syncytial virus interaction with human airway epithelium. Trends Microbiol (2013) 21:238-44. doi:10.1016/j.tim.2013.02.004
53. Guo-Parke H, Canning P, Douglas I, Villenave R, Heaney LG, Coyle PV, et al. Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium. Am J Respir Crit Care Med (2013) 188:842-51. doi:10.1164/rccm.201304-0750OC
54. McNamara PS, Flanagan BF, Selby AM, Hart CA, Smyth RL. Pro-and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J (2004) 23:106-12. doi:10.1183/09031936.03.00048103
55. McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2005) 191:1225-32. doi:10.1086/428855
56. McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child (2003) 88:922-6. doi:10.1136/adc.88.10.922
57. Smith PK, Wang SZ, Dowling KD, Forsyth KD. Leucocyte populations in respiratory syncytial virus-induced bronchiolitis. J Paediatr Child Health (2001) 37:146-51. doi:10.1046/j.1440-1754.2001.00618.x
58. Noah TL, Ivins SS, Murphy P, Kazachkova I, Moats-Staats B, Henderson FW. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin Immunol (2002) 104:86-95. doi:10.1006/clim.2002.5248
59. Mella C, Suarez-Arrabal MC, Lopez S, Stephens J, Fernandez S, Hall MW, et al. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2013) 207:564-73. doi:10.1093/infdis/jis721
60. Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-?B, and proinflammatory cytokines. J Virol (2005) 79:5353-62. doi:10.1128/JVI.79.9.5353-5362.2005
61. Spann KM, Tran K-C, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol (2004) 78:4363-9. doi:10.1128/JVI.78.12.6705.2004
62. Ling Z, Tran KC, Teng MN. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol (2009) 83:3734-42. doi:10.1128/JVI.02434-08
63. Goswami R, Majumdar T, Dhar J, Chattopadhyay S, Bandyopadhyay SK, Verbovetskaya V, et al. Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res (2013) 23:1025-42. doi:10.1038/cr.2013.98
64. Ramaswamy M, Shi L, Monick MM, Hunninghake GW, Look DC. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol (2004) 30:893-900. doi:10.1165/rcmb.2003-0410OC
65. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, et al. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-?B-dependent, interferon-independent mechanism and facilitate virus growth. J Virol (2007) 81:1786-95. doi:10.1128/JVI.01420-06
66. Goritzka M, Durant LR, Pereira C, Salek-Ardakani S, Openshaw PJM, Johansson C. Alpha/Beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol (2014) 88:6128-36. doi:10.1128/JVI.00333-14
67. Johnson TR, Mertz SE, Gitiban N, Hammond S, Legallo R, Durbin RK, et al. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol (2005) 174:7234-41. doi:10.4049/jimmunol.174.11.7234
68. Gill MA, Palucka AK, Barton T, Ghaffar F, Jafri H, Banchereau J, et al. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis (2005) 191:1105-15. doi:10.1086/428589
69. Wang H, Peters N, Schwarze J. Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. J Immunol (2006) 177:6263-70. doi:10.4049/jimmunol.177.9.6263
70. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med (2006) 203:1153-9. doi:10.1084/jem.20052359
71. Marr N, Wang T-I, Kam SHY, Hu YS, Sharma AA, Lam A, et al. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol (2014) 192:948-57. doi:10.4049/jimmunol.1302007
72. Ruckwardt T, Malloy A, Morabito K, Graham B. Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell response. PLoS Pathog (2014) 10(2):e1003934. doi:10.1371/journal.ppat.1003934
73. Munir S, LE Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol (2008) 82:8780-96. doi:10.1128/JVI.00630-08
74. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol (2010) 185:4681-90. doi:10.4049/jimmunol.1001758
75. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology (2009) 128:151-63. doi:10.1111/j.1365-2567.2009.03167.x
76. Larrañaga CL, Ampuero SL, Luchsinger VF, Carrión FA, Aguilar NV, Morales PR, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J (2009) 28:867-73. doi:10.1097/INF.0b013e3181a3ea71
77. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2:732-8. doi:10.1038/90675
78. Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol (2012) 73:248-57. doi:10.1016/j.humimm.2011.12.015
79. Hussell T, Openshaw PJ. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol (1998) 79:2593-601.
80. Johnson KM, Bloom HH, Mufson MA, Chanock RM. Natural reinfection of adults by respiratory syncytial virus. N Engl J Med (1962) 267:68-72. doi:10.1056/NEJM196207122670204
81. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 163:693-8. doi:10.1093/infdis/163.4.693
82. Agoti CN, Mwihuri AG, Sande CJ, Onyango CO, Medley GF, Cane PA, et al. Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J Infect Dis (2012) 206:1532-41. doi:10.1093/infdis/jis570
83. Ohuma EO, Okiro EA, Ochola R, Sande CJ, Cane PA, Medley GF, et al. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol (2012) 176:794-802. doi:10.1093/aje/kws257
84. Okiro EA, White LJ, Ngama M, Cane PA, Medley GF, Nokes DJ. Duration of shedding of respiratory syncytial virus in a community study of Kenyan children. BMC Infect Dis (2010) 10:15. doi:10.1186/1471-2334-10-15
85. Walsh E, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis (2004) 190:373-8. doi:10.1086/421524
86. Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martinez MA, Machado C, et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis (2012) 54:905-12. doi:10.1093/cid/cir955
87. Piedra PA, Jewell AM, Cron SG, Atmar RL, PAUL Glezen W. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine (2003) 21:3479-82. doi:10.1016/S0264-410X(03)00355-4
88. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One (2009) 4:e8088. doi:10.1371/journal.pone.0008088
89. Brandenburg AH, Groen J, Van Steensel-Moll HA, Claas EC, Rothbarth PH, Neijens HJ, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol (1997) 52:97-104. doi:10.1002/(SICI)1096-9071(199705)52:1<97::AID-JMV16>3.0.CO;2-Y
90. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr (1981) 98:708-15. doi:10.1016/S0022-3476(81)80829-3
91. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol (1981) 7:263-71. doi:10.1002/jmv.1890070403
92. Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol (2009) 123:398-403. doi:10.1016/j.jaci.2008.10.043
93. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol (1969) 89:435-48.
94. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 89:449-63.
95. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 89:405-21.
96. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 24:197-202.
97. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 196:859-65. doi:10.1084/jem.20020781
98. Shaw CA, Ciarlet M, Cooper BW, Dionigi L, Keith P, O'brien KB, et al. The path to an RSV vaccine. Curr Opin Virol (2013) 3:332-42. doi:10.1016/j.coviro.2013.05.003
99. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med (2006) 12:905-7. doi:10.1038/nm1456
100. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2009) 15:34-41. doi:10.1038/nm.1894
101. Loebbermann J, Durant L, Thornton H, Johansson C, Openshaw PJ. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci U S A (2013) 110:2987-92. doi:10.1073/pnas.1217580110
102. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine (2003) 21:3465-7. doi:10.1016/S0264-410X(03)00352-9
103. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 31(Suppl 2):B209-15. doi:10.1016/j.vaccine.2012.11.106
104. Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in RSV vaccine development. Expert Rev Vaccines (2014) 13:333-44. doi:10.1586/14760584.2014.878653
105. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 340:1113-7. doi:10.1126/science.1234914
106. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 342:592-8. doi:10.1126/science.1243283
107. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM. The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis (1978) 138:24-32. doi:10.1093/infdis/138.1.24
108. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 24:894-8.
109. Reed JL, Welliver TP, Sims GP, Mckinney L, Velozo L, Avendano L, et al. Innate immune signals modulate antiviral and polyreactive antibody responses during severe respiratory syncytial virus infection. J Infect Dis (2009) 199:1128-38. doi:10.1086/597386
110. Williams JV, Weitkamp JH, Blum DL, Lafleur BJ, Crowe JE Jr. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol Immunol (2009) 47:407-14. doi:10.1016/j.molimm.2009.08.024
111. Siegrist CA, Barrios C, Martinez X, Brandt C, Berney M, Cordova M, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol (1998) 28:4138-48. doi:10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.3.CO;2-C
112. Siegrist CA, Cordova M, Brandt C, Barrios C, Berney M, Tougne C, et al. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine (1998) 16:1409-14. doi:10.1016/S0264-410X(98)00100-5
113. Prabhudas M, Adkins B, Gans H, King C, Levy O, Ramilo O, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol (2011) 12:189-94. doi:10.1038/ni0311-189
114. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol (2004) 4:553-64. doi:10.1038/nri1394
115. Gans HA, Arvin AM, Galinus J, Logan L, Dehovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 280:527-32. doi:10.1001/jama.280.6.527
116. Gans HA, Yasukawa LL, Sung P, Sullivan B, Dehovitz R, Audet S, et al. Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis (2013) 207:574-82. doi:10.1093/infdis/jis719
117. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 9:185-94. doi:10.1038/nri2508
118. Kanswal S, Katsenelson N, Selvapandiyan A, Bram RJ, Akkoyunlu M. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J Immunol (2008) 181:976-90. doi:10.4049/jimmunol.181.2.976
119. Kaur K, Chowdhury S, Greenspan NS, Schreiber JR. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood (2007) 110:2948-54. doi:10.1182/blood-2007-01-069245
120. Pihlgren M, Friedli M, Tougne C, Rochat AF, Lambert PH, Siegrist CA. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol (2006) 176:165-72. doi:10.4049/jimmunol.176.1.165
121. Tian C, Kron GK, Dischert KM, Higginbotham JN, Crowe JE Jr. Low expression of the interleukin (IL)-4 receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells. Immunology (2006) 119:54-62. doi:10.1111/j.1365-2567.2006.02405.x
122. Belnoue E, Pihlgren M, Mcgaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 111:2755-64. doi:10.1182/blood-2007-09-110858
123. Tregoning JS, Wang BL, Mcdonald JU, Yamaguchi Y, Harker JA, Goritzka M, et al. Neonatal antibody responses are attenuated by interferon-gamma produced by NK and T cells during RSV infection. Proc Natl Acad Sci U S A (2013) 110:5576-81. doi:10.1073/pnas.1214247110
124. Mastelic B, Kamath AT, Fontannaz P, Tougne C, Rochat AF, Belnoue E, et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J Immunol (2012) 189:5764-72. doi:10.4049/jimmunol.1201143
125. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol (2013) 3:468-74. doi:10.1016/j.coviro.2013.05.005
126. Hall CB, Powell KR, Macdonald NE, Gala CL, Menegus ME, Suffin SC, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med (1986) 315:77-81. doi:10.1056/NEJM198607103150201
127. Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med (1988) 168:1163-8. doi:10.1084/jem.168.3.1163
128. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 88:1026-33. doi:10.1172/JCI115362
129. Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev (2005) 18:541-55. doi:10.1128/CMR.18.3.541-555.2005
130. Heidema J, Lukens MV, Van Maren WW, Van Dijk ME, Otten HG, Van Vught AJ, et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol (2007) 179:8410-7. doi:10.4049/jimmunol.179.12.8410
131. Lukens MV, Van DE, Pol AC, Coenjaerts FE, Jansen NJ, Kamp VM, et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol (2010) 84:2374-83. doi:10.1128/JVI.01807-09
132. Ruckwardt TJ, Malloy AMW, Gostick E, Price DA, Dash P, Mcclaren JL, et al. Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice. PLoS Pathog (2011) 7:e1002377. doi:10.1371/journal.ppat.1002377
133. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med (2003) 168:633-9. doi:10.1164/rccm.200210-1148OC
134. Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnhofer G, et al. Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med (1999) 160:1263-8. doi:10.1164/ajrccm.160.4.9812025
135. Semple MG, Dankert HM, Ebrahimi B, Correia JB, Booth JA, Stewart JP, et al. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. PLoS One (2007) 2:e1038. doi:10.1371/journal.pone.0001038
136. Kristjansson S, Bjarnarson SP, Wennergren G, Palsdottir AH, Arnadottir T, Haraldsson A, et al. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J Allergy Clin Immunol (2005) 116:805-11. doi:10.1016/j.jaci.2005.07.012
137. Sumino K, Tucker J, Shahab M, Jaffee KF, Visness CM, Gern JE, et al. Antiviral IFN-gamma responses of monocytes at birth predict respiratory tract illness in the first year of life. J Allergy Clin Immunol (2012) 129(1267-1273):e1. doi:10.1016/j.jaci.2012.02.033
138. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC III, Sotnikov AV, et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol (1992) 66:7444-51.
139. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC III, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol (1994) 68:5321-5.
140. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol (1992) 4:493-500. doi:10.1093/intimm/4.4.493
141. Lee Y-M, Miyahara N, Takeda K, Prpich J, Oh A, Balhorn A, et al. IFN-? production during initial infection determines the outcome of reinfection with respiratory syncytial virus. Am J Respir Crit Care Med (2008) 177:208-18. doi:10.1164/rccm.200612-1890OC
142. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med (2002) 196:1381-6. doi:10.1084/jem.20020943
143. Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, Openshaw PJ. Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. Eur Respi J (2002) 20:376-82. doi:10.1183/09031936.02.00249902
144. Renzi PM, Turgeon JP, Yang JP, Drblik SP, Marcotte JE, Pedneault L, et al. Cellular immunity is activated and a Th-2 response is associated with early wheezing in infants after bronchiolitis. J Pediatr (1997) 130:584-93. doi:10.1016/S0022-3476(97)70243-9
145. van der Sande MA, Kidd IM, Goetghebuer T, Martynoga RA, Magnusen A, Allen S, et al. Severe respiratory syncytial virus infection in early life is associated with increased type 2 cytokine production in Gambian children. Clin Exp Allergy (2002) 32:1430-5. doi:10.1046/j.1365-2745.2002.01521.x
146. Castro M, Schweiger T, Yin-Declue H, Ramkumar TP, Christie C, Zheng J, et al. Cytokine response after severe respiratory syncytial virus bronchiolitis in early life. J Allergy Clin Immunol (2008) 122:726.e-33.e. doi:10.1016/j.jaci.2008.07.010
147. Faber TE, Groen H, Welfing M, Jansen KJ, Bont LJ. Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis. J Med Virol (2012) 84:1084-8. doi:10.1002/jmv.23291
148. Stoppelenburg AJ, DE Roock S, Hennus MP, Bont L, Boes M. Elevated th17 response in infants undergoing respiratory viral infection. Am J Pathol (2014) 184:1274-9. doi:10.1016/j.ajpath.2014.01.033
149. Stoppelenburg AJ, Salimi V, Hennus M, Plantinga M, Huis in'tVeld R, Walk J, et al. Local IL-17A potentiates early neutrophil recruitment to the respiratory tract during severe RSV infection. PLoS One (2013) 8:e78461. doi:10.1371/journal.pone.0078461
150. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol (2011) 179:248-58. doi:10.1016/j.ajpath.2011.03.003
151. Hashimoto K, Durbin JE, Zhou W, Collins RD, Ho SB, Kolls JK, et al. Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. J Allergy Clin Immunol (2005) 116:550-7. doi:10.1016/j.jaci.2005.03.051
152. de Almeida Nagata DE, Demoor T, Ptaschinski C, Ting HA, Jang S, Reed M, et al. IL-27R-mediated regulation of IL-17 controls the development of respiratory syncytial virus-associated pathogenesis. Am J Pathol (2014) 184:1807-18. doi:10.1016/j.ajpath.2014.02.004
153. Kallal LE, Hartigan AJ, Hogaboam CM, Schaller MA, Lukacs NW. Inefficient lymph node sensitization during respiratory viral infection promotes IL-17-mediated lung pathology. J Immunol (2010) 185:4137-47. doi:10.4049/jimmunol.1000677
154. Adkins B, Bu Y, Cepero E, Perez R. Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates. J Immunol (2000) 164:2347-53. doi:10.4049/jimmunol.164.5.2347
155. Adkins B, Bu Y, Guevara P. The generation of Th memory in neonates versus adults: prolonged primary Th2 effector function and impaired development of Th1 memory effector function in murine neonates. J Immunol (2001) 166:918-25. doi:10.4049/jimmunol.166.2.918
156. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol (2007) 7:379-90. doi:10.1038/nri2075
157. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by toll-like receptors: distinct responses in newborns and the elderly. Immunity (2012) 37:771-83. doi:10.1016/j.immuni.2012.10.014
158. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, et al. Ontogeny of toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One (2010) 5:e15041. doi:10.1371/journal.pone.0015041
159. Thornburg NJ, Shepherd B, Crowe JE. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. J Virol (2010) 84:12895-902. doi:10.1128/JVI.01273-10
160. Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE, Sprent J, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol (2012) 5:161-72. doi:10.1038/mi.2011.62
161. Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJ. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol (2013) 87:10946-54. doi:10.1128/JVI.01295-13
162. Raiden S, Pandolfi J, Payasliàn F, Anderson M, Rivarola N, Ferrero F, et al. Depletion of circulating regulatory T cells during severe respiratory syncytial virus infection in young children. Am J Respir Crit Care Med (2014) 189:865-8. doi:10.1164/rccm.201311-1977LE
163. Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol (2011) 187:3145-54. doi:10.4049/jimmunol.1100764
164. Loebbermann J, Schnoeller C, Thornton H, Durant L, Sweeney NP, Schuijs M, et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS One (2012) 7:e32371. doi:10.1371/journal.pone.0032371
165. Hoebee B, Bont L, Rietveld E, Van Oosten M, Hodemaekers HM, Nagelkerke NJ, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis (2004) 189:239-47. doi:10.1086/380908
166. Schuurhof A, Janssen R, DE Groot H, Hodemaekers HM, DE Klerk A, Kimpen JL, et al. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. Respir Res (2011) 12:121. doi:10.1186/1465-9921-12-121
167. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity in neonatal mice. Science (1996) 271:1728-30. doi:10.1126/science.271.5256.1728
168. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science (1996) 271:1723-6. doi:10.1126/science.271.5256.1723
169. Sarzotti M, Robbins DS, Hoffman PM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science (1996) 271:1726-8. doi:10.1126/science.271.5256.1726
170. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. BMJ (1982) 284:1665-9. doi:10.1136/bmj.284.6330.1665
171. Henderson J, Hilliard TN, Sherriff A, Stalker D, Shammari NA, Thomas HM, et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol (2005) 16:386-92. doi:10.1111/j.1399-3038.2005.00298.x
172. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet (1999) 354:541-5. doi:10.1016/S0140-6736(98)10321-5
173. Schauer U, Hoffjan S, Bittscheidt J, Köchling A, Hemmis S, Bongartz S, et al. RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur Respir J (2002) 20:1277-83. doi:10.1183/09031936.02.00019902
174. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol (2012) 130:91.e-100.e. doi:10.1016/j.jaci.2012.02.010
175. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax (2010) 2010:27. doi:10.1136/thx.2009.121582
176. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at Age 7. Am J Respir Crit Care Med (2000) 161:1501-7. doi:10.1164/ajrccm.161.5.9906076
177. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med (2005) 171:137-41. doi:10.1164/rccm.200406-730OC
178. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Björkstén B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics (1995) 95:500-5.
179. Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med (2008) 178:1123-9. doi:10.1164/rccm.200804-579OC
180. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med (2013) 368:1791-9. doi:10.1056/NEJMoa1211917
181. Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EAF. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics (2013) 132:811-8. doi:10.1542/peds.2013-0982
182. Simoes EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol (2010) 2010:10. doi:10.1016/j.jaci.2010.05.026
183. Chawes BLK, Poorisrisak P, Johnston SL, Bisgaard H. Neonatal bronchial hyperresponsiveness precedes acute severe viral bronchiolitis in infants. J Allergy Clin Immunol (2012) 130:354.e-61.e. doi:10.1016/j.jaci.2012.04.045
184. Thomsen SF, Van der Sluis S, Stensballe LG, Posthuma D, Skytthe A, et al. Exploring the association between severe respiratory syncytial virus infection and asthma. Am J Respir Crit Care Med (2009) 179:1091-7. doi:10.1164/rccm.200809-1471OC
185. Gern JE, Brooks GD, Meyer P, Chang A, Shen K, Evans MD, et al. Bidirectional interactions between viral respiratory illnesses and cytokine responses in the first year of life. J Allergy Clin Immunol (2006) 117:72-8. doi:10.1016/j.jaci.2005.10.002
186. Goetghebuer T, Isles K, Moore C, Thomson A, Kwiatkowski D, Hull J. Genetic predisposition to wheeze following respiratory syncytial virus bronchiolitis. Clin Exp Allergy (2004) 34:801-3. doi:10.1111/j.1365-2222.2004.1947.x
187. Ermers MJJ, Hoebee B, Hodemaekers HM, Kimman TG, Kimpen JLL, Bont L. IL-13 genetic polymorphism identifies children with late wheezing after respiratory syncytial virus infection. J Allergy Clin Immunol (2007) 119:1086-91. doi:10.1016/j.jaci.2006.12.655
188. Lukacs NW, Tekkanat KK, Berlin A, Hogaboam CM, Miller A, Evanoff H, et al. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms. J Immunol (2001) 167:1060-5. doi:10.4049/jimmunol.167.2.1060
189. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest (1997) 100:226-33. doi:10.1172/JCI119516
190. Dakhama A, Park JW, Taube C, Joetham A, Balhorn A, Miyahara N, et al. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol (2005) 175:1876-83. doi:10.4049/jimmunol.175.3.1876
191. Harker JA, Yamaguchi Y, Culley FJ, Tregoning JS, Openshaw PJ. Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. J Virol (2014) 88:604-11. doi:10.1128/JVI.02620-13
192. Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J Virol (2008) 82:4115-24. doi:10.1128/JVI.02313-07
193. Tregoning JS, Yamaguchi Y, Wang B, Mihm D, Harker JA, Bushell ES, et al. Genetic susceptibility to the delayed sequelae of neonatal respiratory syncytial virus infection is MHC dependent. J Immunol (2010) 185:5384-91. doi:10.4049/jimmunol.1001594
194. Han J, Dakhama A, Jia Y, Wang M, Zeng W, Takeda K, et al. Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand. J Allergy Clin Immunol (2012) 130:1175-86. doi:10.1016/j.jaci.2012.08.033
195. Harker JA, Godlee A, Wahlsten JL, Lee DC, Thorne LG, Sawant D, et al. Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol (2010) 84:4073-82. doi:10.1128/JVI.02014-09
196. Harker JA, Lee DC, Yamaguchi Y, Wang B, Bukreyev A, Collins PL, et al. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol (2010) 84:5294-302. doi:10.1128/JVI.02503-09
197. Yamaguchi Y, Harker JA, Wang B, Openshaw PJ, Tregoning JS, Culley FJ. Pre-exposure to CpG protects against the delayed effects of neonatal RSV infection. J Virol (2012) 86:10456-61. doi:10.1128/JVI.01082-12
198. Wadhwa PD, Buss C, Entringer S, Swanson JM. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Semin Reprod Med (2009) 27:358-68. doi:10.1055/s-0029-1237424
199. You D, Becnel D, Wang K, Ripple M, Daly M, Cormier SA. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir Res (2006) 7:107. doi:10.1186/1465-9921-7-107
200. Siegle JS, Hansbro N, Herbert C, Rosenberg HF, Domachowske JB, Asquith KL, et al. Early-life viral infection and allergen exposure interact to induce an asthmatic phenotype in mice. Respir Res (2010) 11:14. doi:10.1186/1465-9921-11-14
201. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med (2012) 18:1525-30. doi:10.1038/nm.2896
202. Schwarze J, O'Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med (2004) 169:801-5. doi:10.1164/rccm.200308-1203OC
203. Estripeaut D, Torres JP, Somers CS, Tagliabue C, Khokhar S, Bhoj VG, et al. Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model. J Infect Dis (2008) 198:1435-43. doi:10.1086/592714